Top 5 Stocks to Buy Now
→ The Treasury just bought its own debt (From Golden Portfolio) (Ad)tc pixel Free UPB Stock Alerts

Upstream Bio (UPB) Competitors

Upstream Bio logo
$6.36 +0.05 (+0.71%)
Closing price 03:59 PM Eastern
Extended Trading
$6.34 -0.02 (-0.31%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

UPB vs. PAHC, MRVI, ALVO, AVLN, and IMTX

Should you buy Upstream Bio stock or one of its competitors? MarketBeat compares Upstream Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Upstream Bio include Phibro Animal Health (PAHC), Maravai LifeSciences (MRVI), Alvotech (ALVO), Avalyn Pharma (AVLN), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry.

How does Upstream Bio compare to Phibro Animal Health?

Upstream Bio (NASDAQ:UPB) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Upstream Bio currently has a consensus target price of $33.17, suggesting a potential upside of 421.08%. Phibro Animal Health has a consensus target price of $42.50, suggesting a potential upside of 35.52%. Given Upstream Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Upstream Bio is more favorable than Phibro Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Phibro Animal Health
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

99.3% of Phibro Animal Health shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Upstream Bio and Upstream Bio both had 3 articles in the media. Phibro Animal Health's average media sentiment score of 0.77 beat Upstream Bio's score of 0.52 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Upstream Bio
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Phibro Animal Health
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Phibro Animal Health has a net margin of 6.35% compared to Upstream Bio's net margin of -4,718.96%. Phibro Animal Health's return on equity of 37.14% beat Upstream Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Upstream Bio-4,718.96% -43.82% -42.27%
Phibro Animal Health 6.35%37.14%8.57%

Upstream Bio has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Phibro Animal Health has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Upstream Bio$2.85M121.54-$143.44M-$2.91N/A
Phibro Animal Health$1.30B0.98$48.26M$2.3313.46

Summary

Phibro Animal Health beats Upstream Bio on 10 of the 15 factors compared between the two stocks.

How does Upstream Bio compare to Maravai LifeSciences?

Upstream Bio (NASDAQ:UPB) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Upstream Bio currently has a consensus price target of $33.17, indicating a potential upside of 421.08%. Maravai LifeSciences has a consensus price target of $5.50, indicating a potential downside of 4.53%. Given Upstream Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Upstream Bio is more favorable than Maravai LifeSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Maravai LifeSciences
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

Upstream Bio has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

In the previous week, Upstream Bio had 2 more articles in the media than Maravai LifeSciences. MarketBeat recorded 3 mentions for Upstream Bio and 1 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.34 beat Upstream Bio's score of 0.52 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Upstream Bio
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Maravai LifeSciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Maravai LifeSciences has higher revenue and earnings than Upstream Bio. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Upstream Bio$2.85M121.54-$143.44M-$2.91N/A
Maravai LifeSciences$185.74M8.01-$130.77M-$0.71N/A

Maravai LifeSciences has a net margin of -51.07% compared to Upstream Bio's net margin of -4,718.96%. Maravai LifeSciences' return on equity of -17.87% beat Upstream Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Upstream Bio-4,718.96% -43.82% -42.27%
Maravai LifeSciences -51.07%-17.87%-9.08%

50.3% of Maravai LifeSciences shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Upstream Bio and Maravai LifeSciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to Alvotech?

Upstream Bio (NASDAQ:UPB) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Alvotech had 7 more articles in the media than Upstream Bio. MarketBeat recorded 10 mentions for Alvotech and 3 mentions for Upstream Bio. Alvotech's average media sentiment score of 0.85 beat Upstream Bio's score of 0.52 indicating that Alvotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Upstream Bio
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Alvotech
5 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Upstream Bio currently has a consensus price target of $33.17, suggesting a potential upside of 421.08%. Alvotech has a consensus price target of $7.60, suggesting a potential upside of 105.13%. Given Upstream Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Upstream Bio is more favorable than Alvotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Alvotech
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

Alvotech has a net margin of -14.36% compared to Upstream Bio's net margin of -4,718.96%. Alvotech's return on equity of -11.92% beat Upstream Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Upstream Bio-4,718.96% -43.82% -42.27%
Alvotech -14.36%-11.92%-7.59%

Upstream Bio has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Alvotech has higher revenue and earnings than Upstream Bio. Alvotech is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Upstream Bio$2.85M121.54-$143.44M-$2.91N/A
Alvotech$588.90M1.90$27.92M-$0.25N/A

Summary

Alvotech beats Upstream Bio on 8 of the 14 factors compared between the two stocks.

How does Upstream Bio compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Upstream Bio (NASDAQ:UPB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, Upstream Bio had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for Upstream Bio and 1 mentions for Avalyn Pharma. Upstream Bio's average media sentiment score of 0.52 beat Avalyn Pharma's score of 0.00 indicating that Upstream Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avalyn Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Upstream Bio
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Avalyn Pharma has higher earnings, but lower revenue than Upstream Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avalyn PharmaN/AN/AN/AN/AN/A
Upstream Bio$2.85M121.54-$143.44M-$2.91N/A

Avalyn Pharma currently has a consensus target price of $59.00, suggesting a potential upside of 96.08%. Upstream Bio has a consensus target price of $33.17, suggesting a potential upside of 421.08%. Given Upstream Bio's higher probable upside, analysts plainly believe Upstream Bio is more favorable than Avalyn Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalyn Pharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
3.20
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Avalyn Pharma has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Avalyn Pharma's return on equity of 0.00% beat Upstream Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Avalyn PharmaN/A N/A N/A
Upstream Bio -4,718.96%-43.82%-42.27%

Summary

Avalyn Pharma and Upstream Bio tied by winning 5 of the 10 factors compared between the two stocks.

How does Upstream Bio compare to Immatics?

Immatics (NASDAQ:IMTX) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Immatics presently has a consensus price target of $20.80, suggesting a potential upside of 107.58%. Upstream Bio has a consensus price target of $33.17, suggesting a potential upside of 421.08%. Given Upstream Bio's higher possible upside, analysts clearly believe Upstream Bio is more favorable than Immatics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immatics
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Upstream Bio
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

In the previous week, Upstream Bio had 3 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Upstream Bio and 0 mentions for Immatics. Upstream Bio's average media sentiment score of 0.52 beat Immatics' score of 0.00 indicating that Upstream Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Immatics Neutral
Upstream Bio Positive

Immatics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Immatics has a net margin of -572.35% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Immatics' return on equity.

Company Net Margins Return on Equity Return on Assets
Immatics-572.35% -47.36% -39.35%
Upstream Bio -4,718.96%-43.82%-42.27%

Upstream Bio has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immatics$54.60M24.60-$222.26M-$1.99N/A
Upstream Bio$2.85M121.54-$143.44M-$2.91N/A

64.4% of Immatics shares are held by institutional investors. 3.3% of Immatics shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Immatics and Upstream Bio tied by winning 8 of the 16 factors compared between the two stocks.

Get Upstream Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPB vs. The Competition

Export
MetricUpstream BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$343.93M$3.49B$6.54B$12.32B
Dividend YieldN/A2.28%2.68%5.88%
P/E Ratio-2.1920.5025.3923.96
Price / Sales121.54328.65530.17107.90
Price / CashN/A130.9645.2953.76
Price / Book1.018.2610.766.41
Net Income-$143.44M$23.91M$3.56B$337.14M
7 Day Performance3.50%3.05%1.37%-0.48%
1 Month Performance-23.95%2.40%0.81%0.49%
1 Year Performance-44.12%56.35%30.53%28.16%

Upstream Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPB
Upstream Bio
2.0792 of 5 stars		$6.37
+0.7%		$33.17
+421.1%		-41.0%$343.93M$2.85MN/A38
PAHC
Phibro Animal Health
4.9039 of 5 stars		$31.87
-1.3%		$42.50
+33.4%		+24.8%$1.31B$1.30B13.682,475
MRVI
Maravai LifeSciences
2.3472 of 5 stars		$5.01
+1.0%		$5.50
+9.8%		+154.5%$1.28B$185.74MN/A610
ALVO
Alvotech
3.0621 of 5 stars		$3.87
-8.7%		$7.60
+96.4%		-59.5%$1.28B$588.90MN/A1,460
AVLN
Avalyn Pharma
4.6777 of 5 stars		$28.07
-2.4%		$59.00
+110.2%		N/A$1.27BN/AN/A51

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:UPB) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners
Firm That Predicted 2008, 2020, 2022: Right Now Looks Worse
The firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...
TradeSmith | Sponsoredtc pixel
The Treasury just bought its own debt
On April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...
Golden Portfolio | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...
Brownstone Research | Sponsoredtc pixel
VWAV: An Under-the-Radar Defense Play
VisionWave Holdings (NASDAQ: VWAV) is developing a multi-domain defense platform combining AI-powered analytic...
Equiscreen | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel